Category Archives: Global News Feed

Nationwide search for permanent successor underway Nationwide search for permanent successor underway

Read the original here:
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022

Go here to read the rest:
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

See more here:
Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company developing innovative drug delivery technologies for modifying cellular and disease processes in many areas of human disease, today announced a preclinical research collaboration that would offer several opportunities for future development.

Original post:
PCI Biotech and MDimune announce research collaboration agreement

Press Release

Read this article:
Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

FORT WORTH, TX , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that J. Michael (“Mike”) Carmena will step down from the Company’s Board of Directors (the “Board”) and resign as the Company’s Principal Executive Officer, effective December 31, 2021 and Eric Tanzberger has been appointed to the Company’s Board effective January 1, 2022. Concurrently with his appointment to the Board, Mr. Tanzberger was appointed Chair of the Audit Committee.

Read this article:
Sanara MedTech Inc. Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors

PORTLAND, Ore., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces the Company received all required regulatory approvals from the Oregon Liquor Control Commission (“OLCC”) and Clackamas County to complete its previously announced acquisition of the assets of Tozmoz, LLC (“Tozmoz”), an Oregon limited liability company, and it has reached an agreement (“Agreement”) on final terms.

Continued here:
Chalice Brands Ltd. Announces Final Closing and Amended Terms of Acquisition of Tozmoz Assets, A Premier Cannabis Extractor In Oregon

MONTREAL, Dec. 23, 2021 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (TSX Venture: IBT), today announced that on December 22, 2021 the Company’s Board of Directors granted stock options representing a total of 450,000 common shares to its directors and an officer of the Company.

Read more:
IBEX Announces Stock Option Grant to Directors and Employees

REGULATED INFORMATION

Read more from the original source:
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

Basel, December 22, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older1. Cosentyx is now the first biologic indicated for ERA, and the only biologic treatment approved for both ERA and PsA in pediatric patients in the US. These are the second and third approvals for Cosentyx in a pediatric population in the US, and Cosentyx now has a total of five indications across rheumatology and dermatology1.

Continue reading here:
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis